GigCapital (GIG) Gets Another Forward Purchase for its Rights
by Kristi Marvin on 2019-10-02 at 12:34pm

Gig Capital (GIG), announced this morning that they have entered into an additional Forward Purchase Agreement in regards to its Rights Shares, this time, with Kepos Alpha Fund L.P. (“Kepos”).  If you recall, Gig previously entered into a similar agreement last week with Greenhaven Road Capital, whereby Greenhaven agreed to not sell the Shares underlying its Rights and GigCapital agreed to purchase the shares underlying those Rights, including any additional Rights that Greenhaven might acquire, according to a schedule.  Kepos’s schedule is similar, but for a different number of Rights.

The schedule for Kepos is:

  • $1.05 per Right or Additional Right for the first 1,000,000 Rights or Additional Rights (which reflects $10.50 per Share for the first 100,000 Shares);
  • $1.07 per Right or Additional Right for the next 3,329,950 Rights or Additional Rights (which reflects $10.70 per Share for the next 332,995 Shares);

As of October 1, 2019, Kepos held 579,950 Rights, and Kepos may acquire up to 2,750,000 Additional Rights after October 1, 2019 and prior to the closing of the Business Combination. So, again, at worst Kepos gets their Rights Shares purchased 60 days post-closing (or February 15, 2020, whichever is earlier) for $10.50 per Share, and at best, at $10.64 per Share (it appears that Kepos will get one penny less than Greenhaven’s $10.65, assuming Kepos manages to increase their Rights position to 3,329,950).

More importantly, if both Greenhaven and Kepos manage to acquire the full amount of the Rights according to their respective agreements (10,000,000 and 3,329,950), that would total 13,329,950 Rights out of the available 14,375,000, leaving just 1,045,050 Rights for 104,050 Shares.   Additionally, Gig is still (as of today) planning on commencing a cash tender offer for any remaining outstanding Rights.  However, maybe they’ll be able to arrange a third Forward Purchase for the last last million or so.  Any takers?

However, there is also the possibility that if Greenhaven and Kepos are able to max out their Rights purchases, Gig will decide they don’t need to do the tender offer.  After all, the only remaining Shares underlying those outstanding Rights would be a manageable 104,505.  Either way, Gig is already on the hook for potentially ~$14 million that they’ll need to spend to purchase all those Rights back from Greenhaven and Kepos, so do they really want to spend another mil tendering the remaining Rights?  Obviously, it’s going to depend on how many Rights Greenhaven and Kepos are able to purchase, so let’s see what happens.

Stay tuned…

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved